Paromomycin
Clinical data | |
---|---|
Trade names | Catenulin, Aminosidine, Humatin, others[1] |
Other names | monomycin, aminosidine[2] |
AHFS/Drugs.com | Monograph |
MedlinePlus | a601098 |
License data |
|
Pregnancy category |
|
Routes of administration | By mouth, intramuscular, topical[3] |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | Poorly absorbed in the GI tract |
Metabolism | Not available |
Excretion | Fecal |
Identifiers | |
| |
JSmol) | |
| |
| |
(what is this?) (verify) |
Paromomycin is an
Common side effects when taken by mouth include loss of appetite, vomiting, abdominal pain, and diarrhea.[3] When applied to the skin side effects include itchiness, redness, and blisters.[3] When given by injection there may be fever, liver problems, or hearing loss.[3] Use during breastfeeding appears to be safe.[4] Paromomycin is in the aminoglycoside family of medications and causes microbe death by stopping the creation of bacterial proteins.[3]
Paromomycin was discovered in the 1950s from a type of
Medical uses
It is an antimicrobial used to treat intestinal parasitic infections such as cryptosporidiosis[8] and amoebiasis,[9] and other diseases such as leishmaniasis.[10] Paromomycin was demonstrated to be effective against
The route of administration is intramuscular injection and capsule. Paromomycin topical cream with or without gentamicin is an effective treatment for ulcerative cutaneous leishmaniasis, according to the results of a phase-3, randomized, double-blind, parallel group–controlled trial.[11]
Pregnancy and breastfeeding
The medication is poorly absorbed.[12] The effect it may have on the baby is still unknown.[13]
There is limited data regarding the safety of taking paromomycin while breastfeeding but because the drug is poorly absorbed minimal amounts of drug will be secreted in breastmilk.[14]
HIV/AIDS
There is limited evidence that paromomycin can be used in persons coinfected with HIV and Cryptosporidium. A few small trials have showed a reduction in oocyst shedding after treatment with paromomycin.[15]
Adverse effects
The most common adverse effects associated with paromomycin sulfate are abdominal cramps, diarrhea, heartburn, nausea, and vomiting. Long-term use of paromomycin increases the risk for bacterial or fungal infection. Signs of overgrowth include white patches in the oral cavities. Other less common adverse events include myasthenia gravis, kidney damage, enterocolitis, malabsorption syndrome, eosinophilia, headache, hearing loss, ringing in the ear, itching, severe dizziness, and pancreatitis.[16]
Interactions
Paromomycin belongs to the
There are no known food or drink interactions with paromomycin.[17]
Mechanism
Paromomycin is a protein synthesis inhibitor in nonresistant cells by binding to 16S ribosomal RNA.[20] This broad-spectrum antibiotic soluble in water, is very similar in action to neomycin. Antimicrobial activity of paromomycin against Escherichia coli and Staphylococcus aureus has been shown.[21] Paromomycin works as an antibiotic by increasing the error rate in ribosomal translation. Paromomycin binds to a RNA loop, where residues A1492 and A1493 are usually stacked, and expels these two residues. These two residues are involved in detection of correct Watson-Crick pairing between the codon and anti codon. When correct interactions are achieved, the binding provides energy to expel the two residues. Paromomycin binding provides enough energy for residue expulsion and thus results in the ribosome incorporating the incorrect amino acid into the nascent peptide chain.[22]
Pharmacokinetics
Absorption
GI absorption is poor. Any obstructions or factors which impair GI motility may increase the absorption of the drug from the digestive tract. In addition, any structural damage, such as lesions or ulcerations, will tend to increase drug absorption.[23]
For intramuscular (IM) injection, the absorption is rapid. Paromomycin will reach peak plasma concentration within one hour following IM injection.[3] The in-vitro and in-vivo activities parallel those of neomycin.[24]
Elimination
Almost 100% of the oral dose is eliminated unchanged via feces. Any absorbed drug will be excreted in urine.[25]
History
Paromomycin was discovered in the 1950s amongst the secondary metabolites of a variety of Streptomyces then known as Streptomyces krestomuceticus, now known as Streptomyces rimosus. It came into medical use in 1960.[1][4]
References
- ^ ISBN 978-0-8155-1856-3. Archivedfrom the original on 20 December 2016.
- ^ PMID 8036682.
- ^ a b c d e f g h i j "Paromomycin Sulfate". The American Society of Health-System Pharmacists. Archived from the original on 17 November 2016. Retrieved 3 December 2016.
- ^ PMID 18947845.
- hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
- hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.
- ISBN 978-1-284-05756-0.
- ISBN 978-0-85369-499-1.
- ^ "paromomycin" at Dorland's Medical Dictionary
- PMID 17582067.
- PMID 23388004.
- ISBN 978-0-7817-7815-2. Archivedfrom the original on 7 November 2016.
- ISBN 978-0-9815278-8-8.
- ^ "Paromomycin Use During Pregnancy". Drugs.com. Archived from the original on 10 November 2016. Retrieved 10 November 2016.
- ^ ISBN 978-1-4557-4801-3.
- ^ "paromomycin oral : Uses, Side Effects, Interactions, Pictures, Warnings & Dosing - WebMD". WebMD. Archived from the original on 10 November 2016. Retrieved 10 November 2016.
- ^ a b c d "Micromedex".
- ISBN 978-1-4441-4752-0. Archivedfrom the original on 8 September 2017.
- ISBN 978-1-60547-270-6.
- PMID 11587639.
- ^ "Paromomycin" (PDF). Toku-E. 12 January 2010. Archived from the original (PDF) on 26 April 2014. Retrieved 11 June 2012.
- ISBN 978-0-470-57095-1.
- ^ Paromomycin sulfate capsules, USP prescribing information (Report). Detroit, MI: Caraco Pharmaceutical Laboratories. March 1997.
- ^ "Paromomycin". DrugBank. 17 August 2016. Archived from the original on 10 November 2016.
- PMID 7321186.
External links
- Media related to Paromomycin at Wikimedia Commons
- "Paromomycin". Drug Information Portal. U.S. National Library of Medicine.